Friday, August 16, 2013 11:53:28 AM
New Economy Portfolio..peeled off shares in a stock which seems to have given investors mixed message on when their October (Q4) catalyst will be released and what it is for. This is also despite the fact that Aegis raised target price from $2.50-$3 today. http://bit.ly/17RPNX2 The company gave investor guidance yesterday and only discussed Firdapse for 2014 and not CPP-115 or CPP-109 regarding their Tourette's data.
Alert..exited CPRX at $1.42 from $1.31 avg. for a 9% gain. May look to re-enter in the latter part of Q4. I was mainly trading this for the catalyst that I expected would be in October as the company had once guided. They still have a catalyst in announcing enrollment completion but that is in the latter part of Q4.
I had bought expecting October data for CPP-115 in Tourette's syndrome. The company cannot confidently guide for October because it is an investigator initiated (academic) study and not the company study. The study is also for CPp-109 which failed for study in cocaine addiction. The company has never been clear to investors on their slide presentations. It always looked like CP-115 and CP-109 was never mentioned in slides. The company could look to CP-115 for Tourettes but its not being studied there. Very confusing to me and for other investors as well. CPRX never mentions CPP-109 study in their most recent July company presentation and the Tourettes Study. Their only reference is to CPP-115 and Tourette's. Seems misleading as an investor. http://bit.ly/16TZzLi
Disclaimer: http://bit.ly/OlN9DB
Alert..exited CPRX at $1.42 from $1.31 avg. for a 9% gain. May look to re-enter in the latter part of Q4. I was mainly trading this for the catalyst that I expected would be in October as the company had once guided. They still have a catalyst in announcing enrollment completion but that is in the latter part of Q4.
I had bought expecting October data for CPP-115 in Tourette's syndrome. The company cannot confidently guide for October because it is an investigator initiated (academic) study and not the company study. The study is also for CPp-109 which failed for study in cocaine addiction. The company has never been clear to investors on their slide presentations. It always looked like CP-115 and CP-109 was never mentioned in slides. The company could look to CP-115 for Tourettes but its not being studied there. Very confusing to me and for other investors as well. CPRX never mentions CPP-109 study in their most recent July company presentation and the Tourettes Study. Their only reference is to CPP-115 and Tourette's. Seems misleading as an investor. http://bit.ly/16TZzLi
Disclaimer: http://bit.ly/OlN9DB
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
